Octreotide Evidence Guide
Octreotide (Sandostatin) is FDA-approved for acromegaly, carcinoid syndrome, and VIPoma with an extensive evidence base spanning 35+ years of clinical use. As the first synthetic somatostatin analog approved, it remains the most widely used in its class. Multiple Phase 3 trials and decades of real-world data make it the reference compound for somatostatin pharmacology.
Our Take
Octreotide (Sandostatin) is FDA-approved for acromegaly, carcinoid syndrome, and VIPoma with an extensive evidence base spanning 35+ years of clinical use. As the first synthetic somatostatin analog approved, it remains the most widely used in its class. Multiple Phase 3 trials and decades of real-world data make it the reference compound for somatostatin pharmacology.
- Best for
- Acromegaly, carcinoid syndrome, VIPoma, GH/IGF-1 suppression, somatostatin analog pharmacology
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 100-600mcg daily subcutaneous (immediate release) or 20-30mg IM monthly (LAR)
Benefits and Evidence
- Acromegaly Control: Level A, includes human evidence - Normalizes GH and IGF-1 levels in approximately 50-70% of acromegaly patients. Long-acting formulation (LAR) allows monthly dosing with maintained efficacy.
- Carcinoid Symptom Control: Level A, includes human evidence - Effectively controls flushing and diarrhea in carcinoid syndrome. PROMID trial showed significant prolongation of time to tumor progression in metastatic midgut NETs.
- Gallstone Formation: Level A, includes human evidence - Gallstones or biliary sludge develop in 15-30% of patients on long-term therapy due to inhibition of gallbladder motility and bile secretion.
- VIPoma Symptom Control: Level A, includes human evidence - Dramatically reduces profuse watery diarrhea characteristic of VIPomas by inhibiting VIP secretion. Often life-saving in severe cases.
Side Effects and Warnings
- Diarrhea and steatorrhea
- Abdominal pain and nausea
- Cholelithiasis
- Injection site pain
- Hyperglycemia or hypoglycemia
- Bradycardia
- Gallstones - periodic gallbladder ultrasound recommended
- Glucose metabolism changes - monitor in diabetic patients
Research Dosage References
- <strong>Subcutaneous injection</strong> - 50-200 mcg - Two to three times daily - Immediate-release formulation. Starting dose typically 50 mcg three times daily for acromegaly. Titrate based on GH/IGF-1 response.
- <strong>Intramuscular injection</strong> - 20-30 mg - Every 28 days - Sandostatin LAR Depot. Start at 20 mg monthly after 2-week trial of SC octreotide. May increase to 30-40 mg based on response.
Mechanism of Action
Octreotide mimics somatostatin to suppress multiple hormonal pathways: 1. SSTR2/SSTR5 activation: Binds primarily to somatostatin receptor subtypes 2 and 5, mimicking the inhibitory effects of natural somatostatin with a much longer duration of action. 2. Growth hormone suppression: Inhibits GH secretion from somatotroph adenomas in acromegaly, reducing IGF-1 levels and associated symptoms. 3. Gastrointestinal hormone suppression: Inhibits release of serotonin, VIP, gastrin, secretin, and other GI peptide hormones, reducing symptoms of carcinoid syndrome and VIPomas. 4. Antiproliferative effects: Direct and indirect antiproliferative actions on neuroendocrine tumor cells through cell cycle arrest and apoptosis induction.
Legal Status
FDA-approved for acromegaly, severe diarrhea/flushing associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with VIPomas. Available by prescription. Marketed as Sandostatin by Novartis. Generic versions available.
Primary Sources
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID). J Clin Oncol, 2009.
- A meta-analysis of the efficacy of octreotide in acromegaly. J Clin Endocrinol Metab, 2005.
- Long-term treatment of acromegaly with octreotide. Ann Intern Med, 1992.